治疗前血清纤维蛋白原在年轻小细胞肺癌患者中的预后价值：一项横断面研究。
Prognostic value of pretreatment serum fibrinogen in young patients with small cell lung cancer: A cross-sectional study.
作者信息
Tian Juncai, Tian Huohuan, Yang Mengzhu, Yang Linhui, Liu Dan
机构信息
Department of Respiratory and Critical Care Medicine West China Hospital of Sichuan University Chengdu Sichuan China.
出版信息
Health Sci Rep. 2023 Aug 18;6(8):e1507. doi: 10.1002/hsr2.1507. eCollection 2023 Aug.
OBJECTIVE
To explored the prognostic value of pretreatment serum fibrinogen level in young patients with small cell lung cancer (SCLC).
METHODS
The concentrations of serum fibrinogen of 183 young (<50 years old) SCLC patients were measured. The association of baseline serum fibrinogen level and clinical outcome was analyzed by survival analysis.
RESULTS
Hyperfibrinogenemia was significantly associated with American Veterans Administration Lung Study Group stage and surgery treatment. The survival analysis indicated that patients with hypefibrinogenemia had worse outcome than patients with normal fibrinogen. Pretreatment serum fibrinogen level was identified as a worse independent survival predictor in young SCLC. The hazard ratio was 1.420 (95% confidence interval: 1.035-1.947).
CONCLUSIONS
Pretreatment serum fibrinogen is independent associated with overall survival in patients with young SCLC.
目的
探讨治疗前血清纤维蛋白原水平对青年小细胞肺癌（SCLC）患者的预后价值。
方法
测定183例年龄小于50岁的青年SCLC患者的血清纤维蛋白原浓度。采用生存分析方法分析基线血清纤维蛋白原水平与临床结局的相关性。
结果
高纤维蛋白原血症与美国退伍军人管理局肺癌研究组分期及手术治疗显著相关。生存分析表明，高纤维蛋白原血症患者的预后比纤维蛋白原正常的患者差。治疗前血清纤维蛋白原水平被确定为青年SCLC患者较差的独立生存预测指标。风险比为1.420（95%置信区间：1.035 - 1.947）。
结论
治疗前血清纤维蛋白原与青年SCLC患者的总生存独立相关。
Zotero 插件